E

Eiger BioPharmaceuticals, Inc.

53 employees

Eiger is a biopharmaceutical company that develops new antiviral agents against novel targets in the treatment of hepatitis.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Health Care
Medical

Date founded

2008

Funding rounds raised

Total raised

$75M

from 9 investors over 9 rounds

E

Eiger BioPharmaceuticals, Inc. raised $5M on June 7, 2022

Investors: Innovatus Capital Partners

E

Eiger BioPharmaceuticals, Inc. raised $75M on June 7, 2022

Investors: Innovatus Capital Partners

E

Eiger BioPharmaceuticals, Inc. raised $25M on January 4, 2017

Investors: Oxford Finance LLC

E

Eiger BioPharmaceuticals, Inc. raised undisclosed on March 21, 2016

Investors: InterWest Partners

E

Eiger BioPharmaceuticals, Inc. raised $15M on April 15, 2011

Investors: InterWest Partners and Vivo Capital

E

Eiger BioPharmaceuticals, Inc. raised $8.3M on February 25, 2009

Investors: InterWest Partners and Vivo Capital

E

Eiger BioPharmaceuticals, Inc. raised undisclosed on January 1, 2007

Investors: RA Capital Management, L.P.

FAQ